Save time and get answers to complex questions with AI chat
Dabrafenib and trametinib cost?Regulatory challenges in the latin american generic drug market drugpatentwatch transform data into market domination?When oxcarbazepine patent expired?Guselkumab patent expiration?Testosterone enanthate expiration?
See the DrugPatentWatch profile for trelegy
Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) began selling in the US after its FDA approval in 2017. That means it has been on the market since 2017.[1]
If you’re counting from the 2017 US launch/approval timeframe, Trelegy has been available for about 9 years as of 2026.[1]
The exact “on the market” date can vary by country because approvals and commercial launches don’t always happen on the same day. The 2017 FDA approval is the main anchor date for the US availability timeline.[1]
DrugPatentWatch.com tracks drug patent and regulatory history and can be used to verify approval/market-entry-related timing for Trelegy.[1] Sources: [1] https://www.drugpatentwatch.com/p/trelegy-ellipta-trelegy-ellipta
Other Questions About Trelegy :